The Legionnaire disease testing market is projected to experience significant growth, with an expected increase from USD 292 million in 2022 to approximately USD 819.5 million by 2032, reflecting a compound annual growth rate (CAGR) of 9% during the forecast period.
Driving Forces Behind Market Growth
The Legionnaire Disease Testing Market is experiencing steady expansion due to increasing awareness of the disease and the growing need for accurate and timely diagnostics. Legionnaire’s disease, a severe form of pneumonia caused by Legionella bacteria, requires rapid detection to ensure effective treatment. Advances in diagnostic technologies are enhancing the speed and accuracy of testing methods, further boosting market adoption.
A Full Report Overview – https://www.futuremarketinsights.com/reports/legionnaire-disease-testing-market
Increased Competition Spurs Innovation and Accessibility
The competitive landscape of the market is evolving as new entrants introduce innovative and cost-effective testing solutions. This growing competition is making diagnostics more accessible globally, ensuring that healthcare providers and patients benefit from improved affordability and availability of tests.
Future Outlook: Innovation to Meet Rising Demand
As global health systems emphasize early detection and prevention, the market for Legionnaire disease testing is poised for significant growth. Investments in advanced testing methods, including molecular diagnostics and rapid antigen tests, are expected to propel market development further.
The Legionnaire Disease Testing Market is set to play a pivotal role in combating the rising prevalence of the disease, leveraging innovation and competition to provide accessible and effective diagnostic solutions worldwide.
Key Takeaways:
- The global Legionnaire Disease Testing Market was valued at US$ 292 million in 2022 and is projected to grow at a CAGR of 9%, reaching US$ 819.5 million by 2032.
- The market is seeing increased competition, with new players introducing diverse and affordable testing options, improving accessibility.
- The rising demand for reliable diagnostic solutions and heightened awareness of Legionnaire’s disease are driving market growth.
Who are the Key Players in the Legionnaire Disease Testing Market?
The report consists of key players, contributing to the legionnaire disease testing market share. It also consists of organic and inorganic growth strategies adopted by market players to improve their market positions. This exclusive report analyzes the competitive landscape and legionnaire disease testing market share acquired by players to strengthen their market position.
Some of the key players present in the global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.
Recent developments of the Legionnaire Disease Testing Market
- June 2021 – Phigenics has unveiled a new diagnostic tool. To detect Legionella serogroup and species in building water systems, Phigenics Validation Test (PVT) Next Day LegiPlex PCR (Polymerase Chain Reaction). It provides quick findings, and the test met the International Standards Organization’s (ISO) requirements for a limit of detection and specificity.
- March 2021 – IDEXX released the findings of research conducted by WLN, a water quality and technology firm. The IDEXX Legiolert test was compared to the Dutch national reference technique for detecting Legionella pneumophila in the research.
- A two-day free virtual conference on legionnaires’ disease hazards during and after a covid-19 pandemic was held by the Alliance to Prevent Legionnaires’ Disease, a national nonprofit organisation, in August 2020. This virtual conference aimed to increase public awareness of the effective management of risk factors associated with watery Legionnaires’ disease.
Key companies profiled
Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others
Key Segments For Legionnaire Disease Testing Market
Legionnaire Disease Testing Segmentation by Product Type:
- Devices
- Polymerase Chain Reaction System
- Sequencer System
- Test Kits
- Assay Based Test Kits
- Rapid Test Kits
Legionnaire Disease Testing Segmentation by Diagnostic Test:
- Culture Method
- Urinary Antigen Test
- Paired Serology
- Direct Fluorescent Antibody (DFA) Stain
- Polymerase Chain Reaction (PCR)
- Combination Testing (Culture and Urinary Antigen Tests)
Legionnaire Disease Testing Segmentation by End User:
- Hospitals
- Diagnostic Laboratories
- Clinical Research Centers
- Academic Institutes
- Research Centers
- Others
Legionnaire Disease Testing Segmentation by Region:
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Europe (Germany, U.K., France, Italy, Spain, Poland, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, Thailand, Malaysia, Vietnam, Indonesia)
- Oceania (Australia, New Zealand)
- Middle East & Africa (GCC Countries, Turkey, Northern Africa, South Africa)
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Dual Balloon Angioplasty Catheter Market
Cosmetology Market
Cloud Based Drug Discovery Platform Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube